1 |
2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
|
2 |
Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
|
3 |
HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
|
4 |
A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
|
5 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
|
6 |
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
|
7 |
Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
|
8 |
2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
|
9 |
Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
|
10 |
2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
|
11 |
Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
|
12 |
HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D. 2007;8(3):155-68.
|
13 |
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother. 2008 Mar;52(3):901-8.
|
14 |
Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother. 2009 Oct 19;20(2):79-85.
|
15 |
Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment. Biomed Pharmacother. 1999 Dec;53(10):484-6.
|
16 |
Long-acting shot prevents infection with HIV analogue. Nature. doi:10.1038/nature.2014.14819. 04 March 2014
|
17 |
Clinical pipeline report, company report or official report of ViiV Healthcare
|
|
|
|
|
|
|